{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+80%25&page=2", "query": { "intervention": "Glargine 80%", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+80%25&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+80%25&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T20:42:26.147Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01676220", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 878, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 117, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676220" }, { "nct_id": "NCT02738151", "title": "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine, 300U/mL", "type": "DRUG" }, { "name": "Insulin degludec, 100 U/mL", "type": "DRUG" }, { "name": "Non-insulin anti-diabetic treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 929, "start_date": "2016-05-19", "completion_date": "2017-08-15", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 74, "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02738151" }, { "nct_id": "NCT01499095", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lantus (Insulin glargine)", "type": "DRUG" }, { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2011-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2022-03-23", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499095" }, { "nct_id": "NCT00528918", "title": "Comparison of Apidra to Regular Insulin in Hospitalized Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type II" ], "interventions": [ { "name": "Glulisine (Apidra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carl T. Hayden VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 300, "start_date": "2007-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528918" }, { "nct_id": "NCT00975286", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Thiazolidinedione (TZD)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 23, "location_summary": "Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "nct_id": "NCT02058147", "title": "Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Insulin glargine/lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1170, "start_date": "2014-02", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 118, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02058147" }, { "nct_id": "NCT02846233", "title": "Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "GLP1 receptor agonist", "type": "DRUG" }, { "name": "basal insulin", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 22, "start_date": "2016-08", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2020-11-10", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 1, "location_summary": "Fresno, California", "locations": [ { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846233" }, { "nct_id": "NCT00338104", "title": "Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hyperglycemia", "Diabetes" ], "interventions": [ { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 75, "start_date": "2004-07", "completion_date": "2005-05", "has_results": true, "last_update_posted_date": "2009-04-06", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00338104" }, { "nct_id": "NCT03013985", "title": "Glargine U300 Hospital Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Glargine U300", "type": "DRUG" }, { "name": "Glargine U100", "type": "DRUG" }, { "name": "Glulisine Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2017-05-17", "completion_date": "2019-03-22", "has_results": true, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013985" }, { "nct_id": "NCT05114590", "title": "Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2022-01-27", "completion_date": "2023-04-14", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-02T20:42:26.147Z", "location_count": 18, "location_summary": "Canyon Country, California • Huntington Park, California • Lomita, California + 13 more", "locations": [ { "city": "Canyon Country", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05114590" } ] }